Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium Carbonate in Niemann-Pick Disease Type C1
NCT03201627Phase 1Unknown
- Sponsor
- Xinhua Hospital
- Start
- Jul 2017
- Primary completion
- Sep 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lithium carbonate in Niemann-Pick disease type C1 (NPC1), sponsored by Xinhua Hospital. Primary endpoint: NPC Clinical Severity Score at 52 weeks. Status: unknown.
02
Drugs
lithium carbonate
03
Conditions
Niemann-Pick disease type C1 (NPC1)
Beyond the preview
Go deeper on NCT03201627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201627.